Search Keyword:


Search option:


IID00178
UniprotQ96J02
ProteinE3 ubiquitin-protein ligase Itchy homolog
GeneITCH
OrganismHomo sapiens
Sequence LLPS PhaSepDB
PhaSePro
LLPSDB
DrLLPS
Network xml rdf
Structure
Experiment
  :order   disorder   conflict   PDB cluster   ProS   Pfam Domain   SEG
903
 order/disorder by at least rule
     disorder by at least rule
     order by at least rule
 order/disorder by majority rule
Seq 1-155 Monomer :
 Evidence X-RAY 2nq3 A Reference
       Region 2nq3 A 1-12 disorder
       Region 2nq3 A 13-33 order
       Region 2nq3 A 34-35 disorder
       Region 2nq3 A 36-145 order
       Region 2nq3 A 146-155 disorder
Seq 246-270 Hetero dimer : O55043
 Evidence X-RAY 2p4r T Reference
       Region 2p4r T 246-249 disorder
       Region 2p4r T 250-265 order
       Region 2p4r T 266-270 disorder
Seq 249-269 Hetero trimer : IID00279Complex
 Evidence X-RAY 5sxp F Reference
       Region 5sxp F 249-250 disorder
       Region 5sxp F 251-269 order
 Evidence X-RAY 5sxp G Reference
       Region 5sxp G 249-268 order
       Region 5sxp G 269-269 disorder
Seq 328-357 Monomer :
 Evidence NMR 2dmv A Reference
       Region 2dmv A 328-357 order
Seq 359-392 Monomer :
 Evidence NMR 2kyk A Reference
       Region 2kyk A 359-392 order
       Region 2kyk A 391-392 high_rmsd
Seq 433-521 Hetero trimer : Q9H3M7
 Evidence X-RAY 5cq2 A Reference
       Region 5cq2 A 433-437 disorder
       Region 5cq2 A 438-472 order
       Region 5cq2 A 473-476 disorder
       Region 5cq2 A 477-517 order
       Region 5cq2 A 518-521 disorder
Seq 436-474 Hetero octamer : Q9H3M7
 Evidence X-RAY 5dws A Reference
       Region 5dws A 436-436 disorder
       Region 5dws A 437-473 order
       Region 5dws A 474-474 disorder
 Evidence X-RAY 5dws C Reference
       Region 5dws C 436-474 order
 Evidence X-RAY 5dws E Reference
       Region 5dws E 436-437 disorder
       Region 5dws E 438-472 order
       Region 5dws E 473-474 disorder
 Evidence X-RAY 5dws G Reference
       Region 5dws G 436-436 disorder
       Region 5dws G 437-473 order
       Region 5dws G 474-474 disorder
Seq 436-474 Hetero tetramer : Q9H3M7
 Evidence X-RAY 4rof A Reference
       Region 4rof A 436-436 disorder
       Region 4rof A 437-472 order
       Region 4rof A 473-474 disorder
 Evidence X-RAY 4rof B Reference
       Region 4rof B 436-436 disorder
       Region 4rof B 437-472 order
       Region 4rof B 473-474 disorder
Seq 475-514 Hetero tetramer : Q9H3M7
 Evidence X-RAY 5dzd A Reference
       Region 5dzd A 475-477 disorder
       Region 5dzd A 478-514 order
 Evidence X-RAY 5dzd B Reference
       Region 5dzd B 475-475 disorder
       Region 5dzd B 476-514 order
Seq 480-512 Monomer :
 Evidence NMR 2ysf A Reference
       Region 2ysf A 480-512 order
Seq 524-899 Hetero trimer : P0CG48
 Evidence X-RAY 5c7m A Reference
       Region 5c7m A 524-525 disorder
       Region 5c7m A 526-617 order
       Region 5c7m A 618-620 disorder
       Region 5c7m A 621-710 order
       Region 5c7m A 711-711 disorder
       Region 5c7m A 712-899 order
Seq 524-903 Monomer :
 Evidence X-RAY 3tug A Reference
       Region 3tug A 524-524 disorder
       Region 3tug A 525-615 order
       Region 3tug A 616-619 disorder
       Region 3tug A 620-695 order
       Region 3tug A 696-703 disorder
       Region 3tug A 704-706 order
       Region 3tug A 707-733 disorder
       Region 3tug A 734-897 order
       Region 3tug A 898-903 disorder
Seqphosphorylation
    240-240 Phosphoserine; by MAPK8
    263-263 Phosphothreonine; by MAPK8
    273-273 Phosphoserine; by MAPK8
    385-385 Phosphothreonine; by SGK3
    420-420 Phosphotyrosine; by FYN
    450-450 Phosphoserine; by SGK3
Seqacetylation
    2-2 N-acetylserine
 
Prediction
NeProc
Disorder 1-16,123-132,137-439,514-518
Order 17-122,133-136,440-513,519-903
ProS 1-4,123-132,137-144,242-246,332-403,436-439,514-518
AlphaFold
Disorder 1-15,32-36,145-325,408-408,421-438,471-479,585-590,615-621,710-714,897-903
Order 16-31,37-144,326-407,409-420,439-470,480-584,591-614,622-709,715-896
Pfam Hmmer
PF00168 20-99 1.4e-16
PF00397 328-357 2.3e-14
PF00397 360-389 2.9e-14
PF00397 440-469 2.4e-17
PF00397 480-509 2.1e-13
PF00632 598-903 2e-187
SEG 236-247 ,250-267 ,282-298
Function
Function in SwissProt
Acts as an E3 ubiquitin-protein ligase which accepts ubiquitin from an E2 ubiquitin-conjugating enzyme in the form of a thioester and then directly transfers the ubiquitin to targeted substrates (PubMed:14602072, PubMed:17028573, PubMed:16387660, PubMed:18718448, PubMed:18718449, PubMed:11046148, PubMed:19592251, PubMed:19116316, PubMed:19881509, PubMed:20491914, PubMed:20392206, PubMed:20068034, PubMed:23146885, PubMed:24790097, PubMed:25631046). Catalyzes 'Lys-29'-, 'Lys-48'- and 'Lys-63'-linked ubiquitin conjugation (PubMed:17028573, PubMed:18718448, PubMed:19131965, PubMed:19881509). Involved in the control of inflammatory signaling pathways (PubMed:19131965). Essential component of a ubiquitin-editing protein complex, comprising also TNFAIP3, TAX1BP1 and RNF11, that ensures the transient nature of inflammatory signaling pathways (PubMed:19131965). Promotes the association of the complex after TNF stimulation (PubMed:19131965). Once the complex is formed, TNFAIP3 deubiquitinates 'Lys-63' polyubiquitin chains on RIPK1 and catalyzes the formation of 'Lys-48'-polyubiquitin chains (PubMed:19131965). This leads to RIPK1 proteasomal degradation and consequently termination of the TNF- or LPS-mediated activation of NFKB1 (PubMed:19131965). Ubiquitinates RIPK2 by 'Lys-63'-linked conjugation and influences NOD2-dependent signal transduction pathways (PubMed:19592251). Regulates the transcriptional activity of several transcription factors, and probably plays an important role in the regulation of immune response (PubMed:18718448, PubMed:20491914). Ubiquitinates NFE2 by 'Lys-63' linkages and is implicated in the control of the development of hematopoietic lineages (PubMed:18718448). Mediates JUN ubiquitination and degradation (By similarity). Mediates JUNB ubiquitination and degradation (PubMed:16387660). Critical regulator of type 2 helper T (Th2) cell cytokine production by inducing JUNB ubiquitination and degradation (By similarity). Involved in the negative regulation of MAVS-dependent cellular antiviral responses (PubMed:19881509). Ubiquitinates MAVS through 'Lys-48'-linked conjugation resulting in MAVS proteasomal degradation (PubMed:19881509). Following ligand stimulation, regulates sorting of Wnt receptor FZD4 to the degradative endocytic pathway probably by modulating PI42KA activity (PubMed:23146885). Ubiquitinates PI4K2A and negatively regulates its catalytic activity (PubMed:23146885). Ubiquitinates chemokine receptor CXCR4 and regulates sorting of CXCR4 to the degradative endocytic pathway following ligand stimulation by ubiquitinating endosomal sorting complex required for transport ESCRT-0 components HGS and STAM (PubMed:14602072, PubMed:23146885). Targets DTX1 for lysosomal degradation and controls NOTCH1 degradation, in the absence of ligand, through 'Lys-29'-linked polyubiquitination (PubMed:17028573, PubMed:18628966, PubMed:23886940). Ubiquitinates SNX9 (PubMed:20491914). Ubiquitinates MAP3K7 through 'Lys-48'-linked conjugation (By similarity). Involved in the regulation of apoptosis and reactive oxygen species levels through the ubiquitination and proteasomal degradation of TXNIP (PubMed:20068034). Mediates the antiapoptotic activity of epidermal growth factor through the ubiquitination and proteasomal degradation of p15 BID (PubMed:20392206). Ubiquitinates BRAT1 and this ubiquitination is enhanced in the presence of NDFIP1 (PubMed:25631046). Inhibits the replication of influenza A virus (IAV) via ubiquitination of IAV matrix protein 1 (M1) through 'Lys-48'-linked conjugation resulting in M1 proteasomal degradation (PubMed:30328013).